Whole-Cell Breast Cancer Vaccine Plus PD-1 Inhibitor Targets Treatment-Resistant Metastatic Disease
A phase I/II trial tests SV-BR-1-GM, a whole-cell cancer vaccine, combined with the checkpoint inhibitor retifanlimab in patients with metastatic breast cancer.
Summary
This completed phase I/II trial investigated whether combining SV-BR-1-GM — a whole-cell cancer vaccine engineered to secrete GM-CSF — with retifanlimab, a PD-1 immune checkpoint inhibitor, could safely treat patients with metastatic or locally recurrent breast cancer who had exhausted standard therapies. The study enrolled 36 patients across two arms and first established safety in an initial cohort before expanding to compare different timing schedules for the checkpoint inhibitor. Low-dose cyclophosphamide and interferon were also incorporated to enhance immune responsiveness. If the combination proves safe and shows meaningful anti-tumor activity, it could represent a novel immunotherapy strategy for patients who have run out of conventional options — a population with urgent unmet need.
Detailed Summary
Metastatic breast cancer remains one of the most difficult cancers to treat, particularly after standard therapies have failed. Immune checkpoint inhibitors have transformed outcomes in some cancers, but breast cancer has proven largely resistant to immunotherapy alone. Combining tumor-specific vaccines with checkpoint blockade is a strategy designed to first prime the immune system to recognize cancer cells, then remove the brakes that suppress immune activity — potentially producing a more robust and durable anti-tumor response.
This open-label phase I/II trial, sponsored by BriaCell Therapeutics, enrolled 36 patients with metastatic or locally recurrent breast cancer who had already failed standard treatment. The study tested SV-BR-1-GM, a whole-cell vaccine line engineered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF), in combination with retifanlimab, a PD-1 inhibitor. Low-dose cyclophosphamide was included to deplete regulatory T cells and enhance vaccine efficacy, while interferon inoculation was used to boost immune activation at the vaccine site.
The trial was structured in two stages: an initial safety cohort of at least 12 patients assessed for dose-limiting toxicities, followed by an expansion cohort of up to 24 patients randomized to two regimens that differed in the timing of retifanlimab administration relative to vaccination. This design allowed researchers to evaluate not only safety and tolerability but also whether scheduling affected immune response or clinical outcomes.
The study was registered in 2018 and completed in early 2026, meaning full efficacy and safety results have not yet been publicly reported. The combination approach is scientifically compelling because it addresses a known limitation of checkpoint inhibitors — the need for a pre-existing immune response against tumor antigens — by actively generating that response through vaccination.
If results demonstrate meaningful safety and efficacy, this platform could open a new immunotherapy avenue for treatment-refractory metastatic breast cancer, a population with limited options and poor prognosis. Formal publication of results is awaited.
Key Findings
- Phase I/II trial combined SV-BR-1-GM whole-cell vaccine with retifanlimab PD-1 inhibitor in 36 metastatic breast cancer patients.
- Safety was assessed first; expansion proceeded only if dose-limiting toxicities occurred in fewer than 30% of patients.
- Low-dose cyclophosphamide was used to suppress regulatory T cells and amplify vaccine-induced immune responses.
- Two randomized regimens tested different timing of checkpoint inhibitor administration relative to vaccination.
- Trial completed in 2026; full efficacy and safety data have not yet been publicly published.
Methodology
Open-label phase I/II double-arm study enrolling 36 patients with metastatic or locally recurrent breast cancer refractory to standard therapy. An initial safety cohort assessed dose-limiting toxicities before expansion; expansion patients were randomized to two regimens differing in checkpoint inhibitor timing. The multi-component regimen included SV-BR-1-GM vaccine, retifanlimab, low-dose cyclophosphamide, and interferon inoculation.
Study Limitations
This summary is based on the abstract and clinical trial registration only, as the full study results have not been published; no efficacy or detailed safety data are available for evaluation. The small enrollment of 36 patients limits statistical power for definitive efficacy conclusions. The trial's open-label design and lack of a placebo control may introduce bias in outcome assessment.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.